Brief: Surrozen Presents Preliminary Results From Phase 1A Study Of Szn-043 In Healthy Volunteers And Patients With A History Of Liver Cirrhosis At The 2024 European Association For The Study Of The Liver (Easl) In Milan

Surrozen

10/06/2024 13:55

June 10 (Reuters) - Surrozen Inc  SRZN.O :
    * SURROZEN PRESENTS PRELIMINARY RESULTS FROM PHASE 1A STUDY
OF
SZN-043 IN HEALTHY VOLUNTEERS AND PATIENTS WITH A HISTORY OF
LIVER CIRRHOSIS AT THE 2024 EUROPEAN ASSOCIATION FOR THE STUDY
OF THE LIVER (EASL) IN MILAN
    * SURROZEN INC: TREATMENT WITH SZN-043 IN PHASE 1A TRIAL WAS
SAFE
& WELL TOLERATED IN HEALTHY VOLUNTEERS AND PATIENTS WITH A
HISTORY OF LIVER CIRRHOSIS
    * SURROZEN INC: PHASE 1A TRIAL OF SZN-043 DEMONSTRATED
EVIDENCE OF
TARGET ENGAGEMENT AND WNT-PATHWAY MEDIATED PHARMACODYNAMIC
EFFECTS IN LIVER

Source text for Eikon:  ID:nGNX2nVjsh 
Further company coverage:  SRZN.O 

 ((Reuters.Briefs@thomsonreuters.com;))